Cynosure Group’s 10x Genomics TXG Stock Holding History

Cynosure Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,730	Closed	-$546K	–	253
2026 Q1	$546K	Hold	25,730	–	–	0.07%	76
2025 Q4	$420K	Hold	25,730	–	–	0.04%	337
2025 Q3	$301K	Sell	25,730 -24	-0.1%	-$313	0.03%	342
2025 Q2	$298K	Buy	25,754 +24	+0.1%	+$219	0.03%	367
2025 Q1	$225K	Hold	25,730	–	–	0.03%	369
2024 Q4	$369K	Sell	25,730 -15	-0.1%	-$237	0.06%	161
2024 Q3	$581K	Buy	+25,745	New	+$532K	0.08%	137

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cynosure Group's TXG Position: Q2 2026 in Review

Cynosure Group sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 25,730 shares — an estimated $546K sold.

Cynosure Group first reported a position in TXG in Q3 2024 and held it in 7 quarters. The position peaked at $581K in Q3 2024. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Cynosure Group reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
Cynosure Group sold 25,730 10x Genomics shares in Q2 2026, an estimated $546K.
Cynosure Group first reported a position in 10x Genomics in Q3 2024 and held it in 7 quarters.
Cynosure Group's 10x Genomics position peaked at $581K in Q3 2024.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.